By: IPP Bureau
Last updated : September 12, 2025 5:21 pm
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
A.forall announced the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm’s US portfolio. This transaction significantly strengthens A.forall’s marketed portfolio in the United States, marking a major milestone in the company’s sharpened focus on high-quality generics and its commitment to global reach.
The acquired portfolio consists of four well-established hospital medicines that address critical therapeutic needs across neurology, infectious disease, hematology, and anesthesiology. These include Dihydroergotamine Mesylate, used in the treatment of migraine and cluster headaches; Piperacillin/Tazobactam, a broad-spectrum antibiotic for hospital-acquired infections; Tranexamic Acid, for the control of bleeding in surgical and trauma settings; and Phenylephrine Hydrochloride, used to manage hypotension during surgery.
Widely integrated into US hospital protocols, these products are marketed through established distributors and group purchasing organizations, ensuring strong familiarity among healthcare professionals. Commercialization will be led by A.forall’s US subsidiary, Milla Pharmaceuticals Inc.
In addition to the approved medicines, the acquisition includes two late-stage pipeline assets targeting complementary therapeutic areas, which are expected to launch in the coming years.
Steen Vangsgaard, CEO of A.forall, said: “This acquisition fits perfectly with our renewed strategy to develop, commercialize, and add value to medicines, increasing their availability where they matter most. These products expand our US relevance and give us immediate access to a robust portfolio that meets essential therapeutic needs. It is a strategic investment that delivers scale, diversification, and valuable cross-selling opportunities.”
The deal follows A.forall’s recent decision to divest its Retail & Hospital division and focus entirely on generics. This strategy provides a sharper scope, stronger momentum, and a clear direction for growth.